Juan C Arjona Ferreira

No ORCID on file · 4 papers in corpus · active 2022-2024

Study types

  • rct 2
  • article 1
  • other 1

Condition tags

  • endometriosis 4
  • dysmenorrhea 3
  • chronic_pelvic_pain 3
  • dyspareunia 2
rct 2024
Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study
Human Reproduction ·doi:10.1093/humrep/dead263

STUDY QUESTION: What is the efficacy and safety of long-term treatment (up to 2 years) with relugolix combination therapy (CT) in women with moderate to severe endometriosis-associated pain? SUMMARY ANSWER: For up to 2 years, treatment wit…

article 2023
A Plain Language Summary to learn about relugolix combination therapy for the treatment of pain associated with endometriosis
Pain management ·doi:10.2217/pmt-2023-0052

WHAT IS THIS SUMMARY ABOUT?: This is a summary of research studies (known as clinical trials) called SPIRIT 1 and SPIRIT 2. The SPIRIT 1 and SPIRIT 2 studies compared how well a medicine called relugolix combination therapy worked in reliev…

other 2023
Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis
F&S reports ·doi:10.1016/j.xfre.2022.11.010

Treatment of uterine fibroids (UF) and endometriosis (EM) has relied on the surgical skills of gynecologists to improve symptoms and potentially alter the course of these debilitating diseases. Medical management of symptoms for both diseas…

rct 2022
Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2)
Lancet (London, England) ·doi:10.1016/s0140-6736(22)00622-5

BACKGROUND: Endometriosis is a common cause of pelvic pain in women, for which current treatment options are suboptimal. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, combined with estradiol and a progestin, was eva…